Trials / Completed
CompletedNCT01483027
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 428 (actual)
- Sponsor
- Boston Scientific Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy. All patients receive the standard of care chemotherapy with or without the addition of TheraSphere.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | TheraSphere | yttrium 90 microspheres |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2020-08-31
- Completion
- 2020-08-31
- First posted
- 2011-12-01
- Last updated
- 2022-03-29
- Results posted
- 2022-03-29
Locations
131 sites across 13 countries: United States, Austria, Belgium, Canada, China, France, Germany, Italy, Poland, Singapore, South Korea, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01483027. Inclusion in this directory is not an endorsement.